Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Impairment of the protein C pathway plays a central role in the pathogenesis of sepsis. Treatment with recombinant human activated protein C (rhAPC) has been reported to increase survival from severe sepsis. Protein C levels also decrease markedly in acute lung injury, of both septic and nonseptic origin. Low levels of protein C in acute lung injury are associated with poor clinical outcome. The present article discusses the beneficial effects of rhAPC in oleic acid-induced lung injury as well as the controversies between different animal models and the timing of drug administration. The unique bronchial circulation in ovine models seems to be responsible for the beneficial effects of rhAPC when given simultaneously to the injury.
Maybauer
Marc O
MO
Department of Anesthesiology, The University of Texas Medical Branch and Shriners Burns Hospital at Galveston, Galveston, TX 77555-1102, USA.
Traber
Daniel L
DL
Maybauer
Dirk M
DM
D055371:Acute Lung Injury / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D004789:Enzyme Activation / Q000502:physiology; D006801:Humans; D008168:Lung / Q000098:blood supply* / Q000502:physiology; D011486:Protein C / Q000008:administration & dosage* / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000378:metabolism
D011486:Protein C; D011994:Recombinant Proteins